Spine BioPharma completed a $13 million Series B equity financing. Proceeds will support further development of SB-01 For Injection (SB-01, formerly referred to as Remedisc™), a therapeutic for the treatment of degenerative disc disease.
SB-01 is a 7-amino acid chain peptide that binds to and induces downregulation of transforming growth factor, beta 1 (TGFβ1), which is often highly expressed in the degenerated discs of patients with lower back pain. Overexpression of TGFβ1 signaling is associated with inflammation and the degradation of extracellular matrix which maintains the structural integrity of healthy spinal discs. TGFβ1 also stimulates the expression of nerve growth factor, leading to an increase in sensory neurons and discogenic pain. SB-01 treatment of a diseased disc is inteded to antagonize the overexpression of TGFβ1, which decreases inflammation and supports the production of extracellular matrix, maintaining the structural integrity of the disc, decreasing pain and improving pain related disability.
Intradiscal injection of SB-01 in patients with degenerative disc disease was developed as a pharmacological approach to treating chronic back pain, while potentially preventing progression of disc degeneration through TGFβ1 modulation.
Spine BioPharma completed a $13 million Series B equity financing. Proceeds will support further development of SB-01 For Injection (SB-01, formerly referred to as Remedisc™), a therapeutic for the treatment of degenerative disc disease.
SB-01 is a 7-amino acid chain peptide that binds to and induces downregulation of transforming growth factor,...
Spine BioPharma completed a $13 million Series B equity financing. Proceeds will support further development of SB-01 For Injection (SB-01, formerly referred to as Remedisc™), a therapeutic for the treatment of degenerative disc disease.
SB-01 is a 7-amino acid chain peptide that binds to and induces downregulation of transforming growth factor, beta 1 (TGFβ1), which is often highly expressed in the degenerated discs of patients with lower back pain. Overexpression of TGFβ1 signaling is associated with inflammation and the degradation of extracellular matrix which maintains the structural integrity of healthy spinal discs. TGFβ1 also stimulates the expression of nerve growth factor, leading to an increase in sensory neurons and discogenic pain. SB-01 treatment of a diseased disc is inteded to antagonize the overexpression of TGFβ1, which decreases inflammation and supports the production of extracellular matrix, maintaining the structural integrity of the disc, decreasing pain and improving pain related disability.
Intradiscal injection of SB-01 in patients with degenerative disc disease was developed as a pharmacological approach to treating chronic back pain, while potentially preventing progression of disc degeneration through TGFβ1 modulation.
Copy to clipboard 
